The poor prognosis of lung cancer and head and neck cancer has not improved in the past three decades; both are largely tobacco associated. The University of Colorado Cancer Center (UCCC) has a Lung, Head and Neck cancer (LHN) Program with the overall goal of translating scientific research discoveries into preventive and therapeutic interventions to decrease the incidence and mortality of LHN cancers. This application proposes program-wide training, which will best utilize resources and expertise to train the next-generation of basic- and physician-scientists dedicated to LHN research. Based on the NCI's postdoctoral/predoctoral ratio requirement of, we propose to appoint 3 new postdocs and 1 new predoctoral student per award year. The total of 29 training faculty members are selected from active members of UCCC based on their scientific/clinical expertise and track records of mentorship to achieve training of translational LHN research. These faculty members are from both basic science and clinical departments. In addition to laboratory training, we have designed mandatory didactic coursework for all trainees and clinical coursework for non-MD trainees to enhance the trainee's scientific background and the translational aspect of our program. Our specific goal is that the program's trainees will acquire the professional skills for productive academic careers in basic and translational LHN research. We will vigorously select trainees from external and internal trainee pools based on their academic records and commitments to LHN research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Schools of Medicine
United States
Zip Code
Luo, Jingjing; Bian, Li; Blevins, Melanie A et al. (2018) Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clin Cancer Res :
Mishall, Katie M; Beadnell, Thomas C; Kuenzi, Brent M et al. (2017) Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget 8:103014-103031
Dionne, Lai Kuan; Peterman, Eric; Schiel, John et al. (2017) FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation. J Cell Sci 130:4051-4062
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Oweida, Ayman; Bhatia, Shilpa; Hirsch, Kellen et al. (2017) Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. Mol Carcinog 56:1189-1196
Ziemke, Michael; Patil, Tejas; Nolan, Kyle et al. (2017) Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer 109:28-35
Blevins, Melanie A; Huang, Mingxia; Zhao, Rui (2017) The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target. Mol Cancer Ther 16:981-990
Chen, Zhangguo; Gowan, Katherine; Leach, Sonia M et al. (2016) Unexpected effects of different genetic backgrounds on identification of genomic rearrangements via whole-genome next generation sequencing. BMC Genomics 17:823
Morton, J J; Bird, G; Keysar, S B et al. (2016) XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene 35:290-300
Beadnell, Thomas C; Mishall, Katie M; Zhou, Qiong et al. (2016) The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Mol Cancer Ther 15:1952-63

Showing the most recent 10 out of 27 publications